Acute Kidney Failure Stage 3 Clinical Trial
— VExLUS-KRTOfficial title:
Venous Excess and Lung Ultrasound During Continuous Kidney Replacement Therapy in Critically Ill Patients (VExLUS-KRT)
Hemodynamic management of critically ill patients has long been focused on the arterial side of the vasculature by assessing adequate perfusion pressure. However, the venous pressure is also of critical importance. Venous congestion can occur in patients with right ventricular failure, pulmonary hypertension or fluid overload. Fluid overload has harmful effects to end organs causing acute kidney injury (AKI), lung edema, multiorgan dysfunction and death. Vice versa, AKI can aggravate fluid retention and inflammation. The measurement of venous pressure usually relies on central venous pressure (CVP) and inferior vena cava diameter (IVC). However, CVP measurement has been associated with measurement errors and has low accuracy in predicting fluid responsiveness. Moreover, IVC collapsibility or distensibility is a static parameter and is associated with subjective variability. Multiorgan Point-of-Care ultrasound (POCUS) can enhance the management of AKI by enabling the evaluation of renal structural abnormalities and hemodynamic status . POCUS allows the clinician to assess intravascular and pulmonary fluid overload. It has been shown that POCUS is a good parameter to predict global fluid status of the patient . Venous Excess Ultrasound (VEXUS) consists of the evaluation of IVC, hepatic vein, portal vein and intrarenal vein flow pattern. Previous studies showed significant correlation between VExUS score with RRT-free days and guide fluid management in critically ill patients with AKI . VExUS is useful in predicting patients at risk to develop AKI post cardiac surgery . Adding modified lung ultrasound score to the VExUS protocol could help clinician to adjust fluid administration and achieve proper fluid balance during continuous kidney replacement therapy (CKRT). However, the role of using combined VExUS and lung ultrasound in the assessment and guidance of fluid management during CKRT is unknown.
Status | Not yet recruiting |
Enrollment | 209 |
Est. completion date | June 30, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adults (= 18 years of age) 2. Admitted to ICU 3. Plan to initiate CKRT by clinician's judgement Exclusion Criteria: 1. Refuse to participate 2. Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy 3. Kidney tran splant recipient 4. Receive KRT before ICU admission 5. Structural kidney diseases which will interfere with intrarenal doppler ultrasound e.g. renal artery stenosis, autosomal dominant polycystic kidney disease etc. 6. Patients with previously known conditions that interfere with portal doppler assessment, namely liver cirrhosis, severe tricuspid regurgitation with structural heart disease or massive ascites. 7. Underlying disease process with a life expectancy less than 90 days 8. Pregnancy 9. Concomitant severe respiratory distress syndrome 10. Expected life expectancy <48 hours 11. Receiving extracorporeal membrane oxygenation (ECMO) |
Country | Name | City | State |
---|---|---|---|
Thailand | King chula memorial hospital | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Chulalongkorn University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the association between VExLUS scores and all-cause mortality within 28 days | 28 days all cause mortality | 28 days | |
Secondary | To assess the prevalence of venous congestion by using VExLUS in patients who receive CKRT | prevalence of venous congestion | 1 day | |
Secondary | To evaluate the association between VExLUS scores and all-cause mortality within 90 days, KRT-free days, ventilator-free days, vasopressor-free days, ICU-free days, dialysis dependence ay 28 days and 90 days | clinical outcomes | up to 90 days | |
Secondary | - to assess the correlation of VExLUS score with bioelectrical impedance vector analysis (BIVA) parameters and biomarkers | Correlation to BIVA | 1 day | |
Secondary | to evaluate inter-observer variability in determining VExLUS | inter-observer variability | 3 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04622384 -
The Performance of Renal Doppler Ultrasound in Predicting Outcome of Dialysis Weaning
|